Back to Search
Start Over
A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.
- Source :
-
Leukemia & lymphoma [Leuk Lymphoma] 2017 Sep; Vol. 58 (9), pp. 1-2. Date of Electronic Publication: 2017 Feb 20. - Publication Year :
- 2017
- Subjects :
- Adult
Aged
Antineoplastic Agents administration & dosage
Antineoplastic Agents adverse effects
Azepines administration & dosage
Azepines adverse effects
Drug Resistance, Neoplasm
Female
Humans
Lymphoma, Non-Hodgkin mortality
Male
Middle Aged
Protein Kinase Inhibitors administration & dosage
Protein Kinase Inhibitors adverse effects
Pyrimidines administration & dosage
Pyrimidines adverse effects
Recurrence
Retreatment
Treatment Outcome
Antineoplastic Agents therapeutic use
Azepines therapeutic use
Lymphoma, B-Cell drug therapy
Lymphoma, B-Cell pathology
Lymphoma, Non-Hodgkin drug therapy
Lymphoma, Non-Hodgkin pathology
Protein Kinase Inhibitors therapeutic use
Pyrimidines therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1029-2403
- Volume :
- 58
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Leukemia & lymphoma
- Publication Type :
- Report
- Accession number :
- 28278718
- Full Text :
- https://doi.org/10.1080/10428194.2017.1289527